Arguing that the Defense Department might have misread evidence and inflicted harm on the company, a federal judge has thrown WuXi AppTec a lifeline as the research and manufacturing services ...

As Alnylam’s Amvuttra sales disappointed, revenue from BridgeBio’s rival transthyretin amyloidosis (ATTR) drug Attruby came in above analysts’ expectations. | Despite their divergent second-quarter ...

Nearly three decades after its failed bid for FDA approval, the cardiovascular drug levosimendan is still struggling to ...

Bristol Myers Squibb has laid out plans for a $2.3 billion manufacturing facility in Houston, set for completion in 2030. The plant will cover 600,000 square feet and employ nearly 500 people.

Scholar Rock has shed Novo Nordisk’s troubled Catalent facility as a contract manufacturer in its FDA refiling for apitegromab, a candidate for spinal muscular atrophy. The Cambridge, ...

ITM’s application rested on data from the phase 3 Compete trial in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). These malignancies arise in a specialized group of neurons ...

Abbott has enlisted telenovela star Gabriela Spanic to push the message that getting screened for colon cancer doesn’t have ...

Two and a half years into his tenure as Emergent BioSolutions CEO, Joseph Papa is executing another round of restructuring to ...

In a remarkable turnaround, Replimune has reversed the fortune of its melanoma therapy, winning FDA approval after two prior rejections and agency leadership shakeups.  | In a remarkable turnaround, ...

In closing out the TDF/TAF litigation chapter, Gilead is simultaneously moving to a new era of HIV treatment altogether with ...

It’s been years since Big Pharma last witnessed a megamerger. In the late 2010s, Takeda bought Shire, AbbVie acquired ...

After a yearslong struggle, Jazz Pharmaceuticals has called time on Zepzelca as a second-line treatment for small cell lung cancer. | After a yearslong struggle, Jazz Pharmaceuticals has called time ...